Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Burges

Showing results (11-20 of 118) with videos related to

Pageof 12
Sort By:
Investigational New Drugs|November 29, 2008
Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosisAnsgar Brüning, Petra Burger, Marianne Vogel, et al.
Clinical Chemistry and Laboratory Medicine|October 25, 2012
Human epididymis protein 4 (HE4) in benign and malignant diseasesLinda Hertlein, Petra Stieber, Angela Kirschenhofer, et al.
Clinical Chemistry and Laboratory Medicine|May 9, 2007
Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumoursMiriam Lenhard, Caroline Kuemper, Nina Ditsch, et al.
Journal of Visualized Experiments : Jove|March 11, 2024
Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease StagesFabian Trillsch, Juliane Reichenbach, Bastian Czogalla, et al.
Archives of Gynecology and Obstetrics|February 25, 2010
Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patientsLinda Hertlein, Miriam Lenhard, Angela Kirschenhofer, et al.
Gynecologic Oncology|October 4, 2005
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)Pauline Wimberger, Nils Lehmann, Rainer Kimmig, et al.
Cancer Biology & Therapy|December 25, 2008
Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosisAnsgar Brüning, Petra Burger, Marianne Vogel, et al.
Biochemical and Biophysical Research Communications|November 13, 2008
Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cellsAnsgar Brüning, Marianne Vogel, Petra Burger, et al.
Archives of Gynecology and Obstetrics|July 30, 2009
Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovaryAlexander Burges, Ansgar Brüning, Christine Dannenmann, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 30, 2009
Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohortMiriam S Lenhard, Stefanie Mitterer, Carolin Kümper, et al.
Pageof 12

Showing results (11-20 of 118) with videos related to

Sort By:
Pageof 12
Investigational New Drugs|November 29, 2008
Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosisAnsgar Brüning, Petra Burger, Marianne Vogel, et al.
Clinical Chemistry and Laboratory Medicine|October 25, 2012
Human epididymis protein 4 (HE4) in benign and malignant diseasesLinda Hertlein, Petra Stieber, Angela Kirschenhofer, et al.
Clinical Chemistry and Laboratory Medicine|May 9, 2007
Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumoursMiriam Lenhard, Caroline Kuemper, Nina Ditsch, et al.
Journal of Visualized Experiments : Jove|March 11, 2024
Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease StagesFabian Trillsch, Juliane Reichenbach, Bastian Czogalla, et al.
Archives of Gynecology and Obstetrics|February 25, 2010
Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patientsLinda Hertlein, Miriam Lenhard, Angela Kirschenhofer, et al.
Gynecologic Oncology|October 4, 2005
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)Pauline Wimberger, Nils Lehmann, Rainer Kimmig, et al.
Cancer Biology & Therapy|December 25, 2008
Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosisAnsgar Brüning, Petra Burger, Marianne Vogel, et al.
Biochemical and Biophysical Research Communications|November 13, 2008
Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cellsAnsgar Brüning, Marianne Vogel, Petra Burger, et al.
Archives of Gynecology and Obstetrics|July 30, 2009
Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovaryAlexander Burges, Ansgar Brüning, Christine Dannenmann, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 30, 2009
Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohortMiriam S Lenhard, Stefanie Mitterer, Carolin Kümper, et al.
Pageof 12